Genprex to Present at the 2024 BIO International Convention
Presentation to Highlight the Company's GeneTherapies for Cancer and Diabetes
AUSTIN,Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc.("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage genetherapy company focused on developing life-changing therapies forpatients with cancer and diabetes, today announced that itsPresident, Chief Executive Officer and Chief Financial Officer,Ryan Confer, will be providing anoverview of the Company's gene therapies for cancer and diabetes atthe upcoming 2024 BIO International Convention.
Event: 2024 BIO International Convention
Conference Dates: June 3-6,2024
Presentation Date: Monday, June 3,2024
Presentation Time: 2:00 p.m.PT
Venue: San Diego ConventionCenter in Theater 1
Presenter: Ryan Confer,Genprex's President, Chief Executive Officer and Chief FinancialOfficer
Mr. Confer will deliver an overview of the Company's pioneeringgene therapies for cancer and diabetes and will be available forin-person one-on-one meetings with participating attendees throughthe conference platform.
For those interested in meeting Genprex management during theconference, please request a meeting through the conference portalor reach out to Investor Relations at investors@genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical-stagegene therapy company focused on developing life-changing therapiesfor patients with cancer and diabetes. Genprex's technologies aredesigned to administer disease-fighting genes to provide newtherapies for large patient populations with cancer and diabeteswho currently have limited treatment options. Genprex works withworld-class institutions and collaborators to develop drugcandidates to further its pipeline of gene therapies in order toprovide novel treatment approaches. Genprex's oncology programutilizes its systemic, non-viral Oncoprex® Delivery System whichencapsulates the gene-expressing plasmids using lipid-basednanoparticles in a lipoplex form. The resultant product isadministered intravenously, where it is taken up by tumor cellsthat then express tumor suppressor proteins that were deficient inthe tumor. The Company's lead product candidate, Reqorsa®Immunogene Therapy (quaratusugene ozeplasmid), is being evaluatedin three clinical trials as a treatment for NSCLC and SCLC. Each ofGenprex's three lung cancer clinical programs has received a FastTrack Designation from the FDA for the treatment of that patientpopulation, and Genprex's SCLC program has received an FDA OrphanDrug Designation. Genprex's diabetes gene therapy approach iscomprised of a novel infusion process that uses an AAV vector todeliver Pdx1 and MafA genes directly to the pancreas. In models ofType 1 diabetes, GPX-002 transforms alpha cells in the pancreasinto functional beta-like cells, which can produce insulin but maybe distinct enough from beta cells to evade the body's immunesystem. In a similar approach, GPX-002 for Type 2 diabetes, whereautoimmunity is not at play, is believed to rejuvenate andreplenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign upfor press releases and industry updates by visitingtheCompany Website, registering forEmailAlertsand by following Genprex on Twitter, Facebook andLinkedIn.
Cautionary Language Concerning Forward-LookingStatements
Statements contained in this press releaseregarding matters that are not historical facts are"forward-looking statements" within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These forward-lookingstatements are made on the basis of the current beliefs,expectations and assumptions of management, are not guarantees ofperformance and are subject to significant risks and uncertainty.These forward-looking statements should, therefore, be consideredin light of various important factors, including those set forth inGenprex's reports that it files from time to time with theSecurities and Exchange Commission and which you should review,including those statements under "Item 1A – Risk Factors" inGenprex's Annual Report on Form 10-K for the year endedDecember 31, 2023.
Because forward-looking statements are subject to risks anduncertainties, actual results may differ materially from thoseexpressed or implied by such forward-looking statements. Suchstatements include, but are not limited to, statements regarding:Genprex's ability to advance the clinical development,manufacturing and commercialization of its product candidates inaccordance with projected timelines and specifications; the timingand success of Genprex's clinical trials and regulatory approvals;the effect of Genprex's product candidates, alone and incombination with other therapies, on cancer and diabetes; Genprex'sfuture growth and financial status, including Genprex's ability tomaintain compliance with the continued listing requirements of TheNasdaq Capital Market and to continue as a going concern and toobtain capital to meet its long-term liquidity needs on acceptableterms, or at all; Genprex's commercial and strategic partnerships,including those with its third party vendors, suppliers andmanufacturers and their ability to successfully perform and scaleup the manufacture of its product candidates; and Genprex'sintellectual property and licenses.
These forward-looking statements should not be relied upon aspredictions of future events and Genprex cannot assure you that theevents or circ*mstances discussed or reflected in these statementswill be achieved or will occur. If such forward-looking statementsprove to be inaccurate, the inaccuracy may be material. You shouldnot regard these statements as a representation or warranty byGenprex or any other person that Genprex will achieve itsobjectives and plans in any specified timeframe, or at all. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date of this press release.Genprex disclaims any obligation to publicly update or release anyrevisions to these forward-looking statements, whether as a resultof new information, future events or otherwise, after the date ofthis press release or to reflect the occurrence of unanticipatedevents, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX InvestorRelations
investors@genprex.com
GNPX Media Contact
KalynDabbs
media@genprex.com
View original content to downloadmultimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-the-2024-bio-international-convention-302159043.html
SOURCE Genprex, Inc.
Copyright 2024 PR Newswire
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From May 2024 to Jun 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Jun 2023 to Jun 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
Genprex, Inc. News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Genprex to Present at the 2024 BIO International Convention","short_text":" Genprex to Present at the 2024 BIO International Convention\nPR Newswire\nAUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes\nAUSTIN, Texas...","one_line_short_text":" Genprex to Present at the 2024 BIO International Convention\nPR Newswire\nAUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's Gene...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93950807\/genprex-to-present-at-the-2024-bio-international-c","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1717072260,"date":"Thu May 30, 2024 ","time":"8:31 AM (2 weeks ago)","full_date":"May 30, 2024 8:31 AM","post_time":"May 30 2024","article_id":93950807,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 424B5 - Prospectus [Rule 424(b)(5)]","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93892025\/form-424b5-prospectus-rule-424b5","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716237351,"date":"Mon May 20, 2024 ","time":"4:35 PM (3 weeks ago)","full_date":"May 20, 2024 4:35 PM","post_time":"May 20 2024","article_id":93892025,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93860553\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715804154,"date":"Wed May 15, 2024 ","time":"4:15 PM (4 weeks ago)","full_date":"May 15, 2024 4:15 PM","post_time":"May 15 2024","article_id":93860553,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer","short_text":" Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer\nPR Newswire\nAUSTIN, Texas, May 14, 2024...","one_line_short_text":" Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93845423\/genprex-doses-first-patient-in-acclaim-3-clinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715689860,"date":"Tue May 14, 2024 ","time":"8:31 AM (4 weeks ago)","full_date":"May 14, 2024 8:31 AM","post_time":"May 14 2024","article_id":93845423,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors","short_text":" Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors\nPR Newswire\nAUSTIN, Texas, May 13, 2024 Follows the Recent Appointment of Ryan Confer as Genprex...","one_line_short_text":" Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors\nPR Newswire\nAUSTIN, Texas, May 13, 2024 Follows...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93834884\/genprex-announces-the-appointment-of-jose-a-moren","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715603460,"date":"Mon May 13, 2024 ","time":"8:31 AM (1 month ago)","full_date":"May 13, 2024 8:31 AM","post_time":"May 13 2024","article_id":93834884,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93814538\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715256667,"date":"Thu May 09, 2024 ","time":"8:11 AM (1 month ago)","full_date":"May 9, 2024 8:11 AM","post_time":"May 09 2024","article_id":93814538,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner","short_text":" Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner\nPR Newswire\nAUSTIN, Texas, May 8, 2024 Ryan Confer Appointed Genprex President and CEO and to its Board...","one_line_short_text":" Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner\nPR Newswire\nAUSTIN, Texas, May 8, 2024 Ryan Confer...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93808405\/genprex-announces-the-passing-of-its-co-founder-an","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715206080,"date":"Wed May 08, 2024 ","time":"6:08 PM (1 month ago)","full_date":"May 8, 2024 6:08 PM","post_time":"May 08 2024","article_id":93808405,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex to Present and Participate at Upcoming May Investor and Industry Conferences","short_text":" Genprex to Present and Participate at Upcoming May Investor and Industry Conferences\nPR Newswire\nAUSTIN, Texas, May. 1, 2024 AUSTIN, Texas, May. 1, 2024 \/PRNewswire\/ -- Genprex, Inc. (\"Genprex...","one_line_short_text":" Genprex to Present and Participate at Upcoming May Investor and Industry Conferences\nPR Newswire\nAUSTIN, Texas, May. 1, 2024 AUSTIN, Texas, May...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93760052\/genprex-to-present-and-participate-at-upcoming-may","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1714566660,"date":"Wed May 01, 2024 ","time":"8:31 AM (1 month ago)","full_date":"May 1, 2024 8:31 AM","post_time":"May 01 2024","article_id":93760052,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting","short_text":" Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery System for the Treatment of Lung Cancers at the 2024...","one_line_short_text":" Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93624959\/genprex-collaborators-report-positive-preclinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712665860,"date":"Tue Apr 09, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 9, 2024 8:31 AM","post_time":"April 09 2024","article_id":93624959,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer","short_text":" Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer\nPR Newswire\nAUSTIN, Texas, April 3, 2024...","one_line_short_text":" Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93598745\/genprex-expands-clinical-trial-sites-for-acclaim-3","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712147460,"date":"Wed Apr 03, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 3, 2024 8:31 AM","post_time":"April 03 2024","article_id":93598745,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System","short_text":" Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System\nPR Newswire\nAUSTIN, Texas, April 2, 2024 NPRL2 Gene Therapy Induces Anti-Tumor...","one_line_short_text":" Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System\nPR Newswire\nAUSTIN, Texas...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93590057\/genprex-collaborators-publish-positive-preclinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712061060,"date":"Tue Apr 02, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 2, 2024 8:31 AM","post_time":"April 02 2024","article_id":93590057,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","short_text":" Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules\nPR Newswire\nAUSTIN, Texas, March 22, 2024 AUSTIN, Texas, March 22, 2024 \/PRNewswire\/...","one_line_short_text":" Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules\nPR Newswire\nAUSTIN, Texas, March 22...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93536928\/genprex-announces-closing-of-6-5-million-register","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1711138200,"date":"Fri Mar 22, 2024 ","time":"4:10 PM (3 months ago)","full_date":"March 22, 2024 4:10 PM","post_time":"March 22 2024","article_id":93536928,"source_id":"prnus","media_url":null,"press_release":true}],"All News": [{"headline":"Genprex to Present at the 2024 BIO International Convention","short_text":" Genprex to Present at the 2024 BIO International Convention\nPR Newswire\nAUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes\nAUSTIN, Texas...","one_line_short_text":" Genprex to Present at the 2024 BIO International Convention\nPR Newswire\nAUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's Gene...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93950807\/genprex-to-present-at-the-2024-bio-international-c","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1717072260,"date":"Thu May 30, 2024 ","time":"8:31 AM (2 weeks ago)","full_date":"May 30, 2024 8:31 AM","post_time":"May 30 2024","article_id":93950807,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 424B5 - Prospectus [Rule 424(b)(5)]","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93892025\/form-424b5-prospectus-rule-424b5","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716237351,"date":"Mon May 20, 2024 ","time":"4:35 PM (3 weeks ago)","full_date":"May 20, 2024 4:35 PM","post_time":"May 20 2024","article_id":93892025,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93860553\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715804154,"date":"Wed May 15, 2024 ","time":"4:15 PM (4 weeks ago)","full_date":"May 15, 2024 4:15 PM","post_time":"May 15 2024","article_id":93860553,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer","short_text":" Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer\nPR Newswire\nAUSTIN, Texas, May 14, 2024...","one_line_short_text":" Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa\u00ae Immunogene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93845423\/genprex-doses-first-patient-in-acclaim-3-clinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715689860,"date":"Tue May 14, 2024 ","time":"8:31 AM (4 weeks ago)","full_date":"May 14, 2024 8:31 AM","post_time":"May 14 2024","article_id":93845423,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors","short_text":" Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors\nPR Newswire\nAUSTIN, Texas, May 13, 2024 Follows the Recent Appointment of Ryan Confer as Genprex...","one_line_short_text":" Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors\nPR Newswire\nAUSTIN, Texas, May 13, 2024 Follows...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93834884\/genprex-announces-the-appointment-of-jose-a-moren","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715603460,"date":"Mon May 13, 2024 ","time":"8:31 AM (1 month ago)","full_date":"May 13, 2024 8:31 AM","post_time":"May 13 2024","article_id":93834884,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93814538\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715256667,"date":"Thu May 09, 2024 ","time":"8:11 AM (1 month ago)","full_date":"May 9, 2024 8:11 AM","post_time":"May 09 2024","article_id":93814538,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner","short_text":" Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner\nPR Newswire\nAUSTIN, Texas, May 8, 2024 Ryan Confer Appointed Genprex President and CEO and to its Board...","one_line_short_text":" Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner\nPR Newswire\nAUSTIN, Texas, May 8, 2024 Ryan Confer...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93808405\/genprex-announces-the-passing-of-its-co-founder-an","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1715206080,"date":"Wed May 08, 2024 ","time":"6:08 PM (1 month ago)","full_date":"May 8, 2024 6:08 PM","post_time":"May 08 2024","article_id":93808405,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex to Present and Participate at Upcoming May Investor and Industry Conferences","short_text":" Genprex to Present and Participate at Upcoming May Investor and Industry Conferences\nPR Newswire\nAUSTIN, Texas, May. 1, 2024 AUSTIN, Texas, May. 1, 2024 \/PRNewswire\/ -- Genprex, Inc. (\"Genprex...","one_line_short_text":" Genprex to Present and Participate at Upcoming May Investor and Industry Conferences\nPR Newswire\nAUSTIN, Texas, May. 1, 2024 AUSTIN, Texas, May...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93760052\/genprex-to-present-and-participate-at-upcoming-may","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1714566660,"date":"Wed May 01, 2024 ","time":"8:31 AM (1 month ago)","full_date":"May 1, 2024 8:31 AM","post_time":"May 01 2024","article_id":93760052,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting","short_text":" Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery System for the Treatment of Lung Cancers at the 2024...","one_line_short_text":" Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa\u00ae and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex\u00ae Delivery...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93624959\/genprex-collaborators-report-positive-preclinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712665860,"date":"Tue Apr 09, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 9, 2024 8:31 AM","post_time":"April 09 2024","article_id":93624959,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer","short_text":" Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer\nPR Newswire\nAUSTIN, Texas, April 3, 2024...","one_line_short_text":" Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa\u00ae Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93598745\/genprex-expands-clinical-trial-sites-for-acclaim-3","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712147460,"date":"Wed Apr 03, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 3, 2024 8:31 AM","post_time":"April 03 2024","article_id":93598745,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System","short_text":" Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System\nPR Newswire\nAUSTIN, Texas, April 2, 2024 NPRL2 Gene Therapy Induces Anti-Tumor...","one_line_short_text":" Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex\u00ae Delivery System\nPR Newswire\nAUSTIN, Texas...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93590057\/genprex-collaborators-publish-positive-preclinical","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1712061060,"date":"Tue Apr 02, 2024 ","time":"8:31 AM (2 months ago)","full_date":"April 2, 2024 8:31 AM","post_time":"April 02 2024","article_id":93590057,"source_id":"prnus","media_url":null,"press_release":true},{"headline":"Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","short_text":" Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules\nPR Newswire\nAUSTIN, Texas, March 22, 2024 AUSTIN, Texas, March 22, 2024 \/PRNewswire\/...","one_line_short_text":" Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules\nPR Newswire\nAUSTIN, Texas, March 22...","link":"https:\/\/www.advfn.com\/stock-market\/NASDAQ\/GNPX\/stock-news\/93536928\/genprex-announces-closing-of-6-5-million-register","source":"PR Newswire (US)","source_logo":"\/common\/images\/news-sources\/prnus.png","tags":[],"timestamp":1711138200,"date":"Fri Mar 22, 2024 ","time":"4:10 PM (3 months ago)","full_date":"March 22, 2024 4:10 PM","post_time":"March 22 2024","article_id":93536928,"source_id":"prnus","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More Genprex, Inc. News Articles
